RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases

Mol Aspects Med. 2022 Oct 15:101148. doi: 10.1016/j.mam.2022.101148. Online ahead of print.ABSTRACTAdvances in genome sequencing have greatly facilitated the identification of genomic variants underlying rare neurodevelopmental and neurodegenerative disorders. Understanding the fundamental causes of rare monogenic disorders has made gene therapy a possible treatment approach for these conditions. RNA interference (RNAi) technologies such as small interfering RNA (siRNA), microRNA (miRNA), and short hairpin RNA (shRNA), and other oligonucleotide-based modalities such as antisense oligonucleotides (ASOs) are being developed as potential therapeutic approaches for manipulating expression of the genes that cause a variety of neurological diseases. Here, we offer a brief review of the mechanism of action of these RNAi approaches; provide deeper discussion of the advantages, challenges, and specific considerations related to the development of RNAi therapeutics for neurological disease; and highlight examples of rare neurological diseases for which RNAi therapeutics hold great promise.PMID:36257857 | DOI:10.1016/j.mam.2022.101148
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research